MX2021015356A - Anticuerpos y fragmentos de anticuerpos anti-epcam condicionalmente activos, sus inmunoconjugados y usos de estos. - Google Patents
Anticuerpos y fragmentos de anticuerpos anti-epcam condicionalmente activos, sus inmunoconjugados y usos de estos.Info
- Publication number
- MX2021015356A MX2021015356A MX2021015356A MX2021015356A MX2021015356A MX 2021015356 A MX2021015356 A MX 2021015356A MX 2021015356 A MX2021015356 A MX 2021015356A MX 2021015356 A MX2021015356 A MX 2021015356A MX 2021015356 A MX2021015356 A MX 2021015356A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody fragments
- immunoconjugates
- chain variable
- variable region
- active anti
- Prior art date
Links
- 102000008394 Immunoglobulin Fragments Human genes 0.000 title abstract 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 title abstract 3
- 229940127121 immunoconjugate Drugs 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 abstract 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
- A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Polipéptidos aislados que tienen una región variable de la cadena pesada y/o una región variable de la cadena liviana que se fija específicamente a la proteína EpCAM, así como anticuerpos y fragmentos de anticuerpos que contienen la región variable de la cadena pesada y/o la región variable de la cadena liviana que se fija a la proteína EpCAM; también se proporcionan composiciones y kits farmacéuticos que comprenden el polipéptido y anticuerpos y fragmentos de anticuerpos que contienen el polipéptido.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962860092P | 2019-06-11 | 2019-06-11 | |
PCT/US2020/037096 WO2020252095A1 (en) | 2019-06-11 | 2020-06-10 | Conditionally active anti-epcam antibodies, antibody fragments, their immunoconjugates and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021015356A true MX2021015356A (es) | 2022-04-06 |
Family
ID=73781730
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021015356A MX2021015356A (es) | 2019-06-11 | 2020-06-10 | Anticuerpos y fragmentos de anticuerpos anti-epcam condicionalmente activos, sus inmunoconjugados y usos de estos. |
Country Status (10)
Country | Link |
---|---|
US (2) | US11851499B2 (es) |
EP (1) | EP3983446A4 (es) |
JP (1) | JP7387196B2 (es) |
KR (1) | KR102560876B1 (es) |
CN (1) | CN114026127A (es) |
AU (1) | AU2020292304B2 (es) |
CA (1) | CA3143039A1 (es) |
IL (1) | IL288753A (es) |
MX (1) | MX2021015356A (es) |
WO (1) | WO2020252095A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3226397A1 (en) | 2021-07-22 | 2023-01-26 | Ignacio Moraga GONZALEZ | Therapeutic muteins |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008122551A2 (en) | 2007-04-04 | 2008-10-16 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Anti-epcam antibody and uses thereof |
ES2661310T3 (es) | 2009-03-09 | 2018-03-28 | Bioatla, Llc | Proteínas mirac |
CN101701039B (zh) | 2009-11-06 | 2011-10-26 | 中国人民解放军第四军医大学 | Fmu-epcam-2a9单克隆抗体的轻链和重链可变区 |
TW201125583A (en) | 2009-12-23 | 2011-08-01 | Bioalliance Cv | Anti-EpCAM antibodies that induce apoptosis of cancer cells and methods using same |
PT2647707T (pt) | 2010-11-30 | 2018-11-15 | Chugai Pharmaceutical Co Ltd | Agente terapêutico indutor de toxicidade |
TWI485161B (zh) * | 2012-03-02 | 2015-05-21 | Academia Sinica | 抗上皮細胞黏著分子(EpCAM)抗體及其使用方法 |
EP2943511B1 (en) | 2013-01-14 | 2019-08-07 | Xencor, Inc. | Novel heterodimeric proteins |
KR20160058954A (ko) | 2013-10-02 | 2016-05-25 | 비벤티아 바이오 인코포레이티드 | 항-epcam 항체 및 사용 방법 |
US20170002060A1 (en) | 2014-01-08 | 2017-01-05 | Moderna Therapeutics, Inc. | Polynucleotides for the in vivo production of antibodies |
US9777073B2 (en) | 2014-07-21 | 2017-10-03 | Wuhan Yzy Biopharma Co., Ltd. | Construction and application of bispecific antibody EpCAM×CD3 |
CA2959141A1 (en) * | 2014-08-28 | 2016-03-03 | Bioatla, Llc | Conditionally active chimeric antigen receptors for modified t-cells |
EP3189152A4 (en) * | 2014-09-03 | 2018-04-04 | BioAtla LLC | Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts |
CA2963719A1 (en) * | 2014-11-10 | 2016-05-19 | F. Hoffmann-La Roche Ag | Anti-il-1beta antibodies and methods of use |
KR20170083095A (ko) | 2014-11-11 | 2017-07-17 | 아뮤닉스 오퍼레이팅 인코포레이티드 | 표적화된 xten 접합체 조성물 및 이의 제조 방법 |
-
2020
- 2020-06-10 MX MX2021015356A patent/MX2021015356A/es unknown
- 2020-06-10 EP EP20823266.0A patent/EP3983446A4/en active Pending
- 2020-06-10 US US17/616,113 patent/US11851499B2/en active Active
- 2020-06-10 CA CA3143039A patent/CA3143039A1/en active Pending
- 2020-06-10 KR KR1020227000242A patent/KR102560876B1/ko active IP Right Grant
- 2020-06-10 WO PCT/US2020/037096 patent/WO2020252095A1/en unknown
- 2020-06-10 CN CN202080042594.6A patent/CN114026127A/zh active Pending
- 2020-06-10 JP JP2021573310A patent/JP7387196B2/ja active Active
- 2020-06-10 AU AU2020292304A patent/AU2020292304B2/en active Active
-
2021
- 2021-12-07 IL IL288753A patent/IL288753A/en unknown
-
2023
- 2023-11-14 US US18/508,938 patent/US20240117067A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
IL288753A (en) | 2022-02-01 |
EP3983446A1 (en) | 2022-04-20 |
KR20220019761A (ko) | 2022-02-17 |
US11851499B2 (en) | 2023-12-26 |
EP3983446A4 (en) | 2023-04-19 |
AU2020292304A1 (en) | 2022-01-06 |
AU2020292304B2 (en) | 2023-03-30 |
JP7387196B2 (ja) | 2023-11-28 |
CN114026127A (zh) | 2022-02-08 |
US20240117067A1 (en) | 2024-04-11 |
TW202112820A (zh) | 2021-04-01 |
CA3143039A1 (en) | 2020-12-17 |
WO2020252095A1 (en) | 2020-12-17 |
US20220315664A1 (en) | 2022-10-06 |
JP2022531504A (ja) | 2022-07-06 |
KR102560876B1 (ko) | 2023-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022010487A (es) | Anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados y usos de los mismos. | |
MX2022009915A (es) | Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos. | |
MX2021005048A (es) | Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos. | |
MX2022016192A (es) | Anticuerpos anti-nectina-4 condicionalmente activos. | |
WO2020068752A8 (en) | SIRPα BINDING PROTEINS AND METHODS OF USE THEREOF | |
WO2019224716A3 (en) | Antibodies specific for gucy2c and uses thereof | |
AU2018271872A1 (en) | A protein binding NKG2D, CD16 and ROR1 or ROR2 | |
EP3882270A3 (en) | Proteins binding nkg2d, cd16, and egfr, ccr4, or pd-l1 | |
AU2018338322A1 (en) | A33 antibody compositions and methods of using the same in radioimmunotherapy | |
PE20120549A1 (es) | Proteinas biespecificas de union a antigenos | |
EA202190542A1 (ru) | Сконструированные биспецифические белки | |
EA201992526A1 (ru) | Стабильные составы анти-ctla4 антител, отдельно и в комбинации с антителами против рецептора 1 программируемой смерти (pd-1), и способы их применения | |
EA201491599A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
EA201390146A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
WO2018187356A3 (en) | Protein antigens and uses thereof | |
SG10201801219VA (en) | Anti-HER2 Antibodies | |
WO2020051333A8 (en) | Anti-avb8 antibodies and compositions and uses thereof | |
EA201491575A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
WO2019056023A3 (en) | Claudin6 antibodies and methods of treating cancer | |
PH12020551661A1 (en) | Anti-pd-l1 antibody and use thereof | |
WO2022082073A3 (en) | Compositions and methods for muc18 targeting | |
MX2021015356A (es) | Anticuerpos y fragmentos de anticuerpos anti-epcam condicionalmente activos, sus inmunoconjugados y usos de estos. | |
PE20200487A1 (es) | Proteinas de union al antigeno anti-jagged1 | |
MX2022003465A (es) | Anticuerpo monoclonal contra proteína de activación de fibroblasto canino de reacción cruzada con proteína de activación de fibroblasto (fap) de ratón y humana. | |
MX2022000379A (es) | Anticuerpos que se unen a celulas cancerosas yque dirigen radionucleidos a dichas celulas. |